Thermo Fisher Scientific Inc. $TMO Stake Lifted by Signal Advisors Wealth LLC

Signal Advisors Wealth LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 77.5% in the 2nd quarter, HoldingsChannel reports. The fund owned 2,302 shares of the medical research company’s stock after acquiring an additional 1,005 shares during the period. Signal Advisors Wealth LLC’s holdings in Thermo Fisher Scientific were worth $933,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Revolve Wealth Partners LLC lifted its stake in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Intergy Private Wealth LLC lifted its stake in Thermo Fisher Scientific by 5.8% during the first quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company’s stock valued at $208,000 after purchasing an additional 23 shares during the last quarter. Root Financial Partners LLC lifted its stake in Thermo Fisher Scientific by 5.0% during the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company’s stock valued at $252,000 after purchasing an additional 24 shares during the last quarter. Rossmore Private Capital lifted its stake in Thermo Fisher Scientific by 0.5% during the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock valued at $2,315,000 after purchasing an additional 24 shares during the last quarter. Finally, ARS Wealth Advisors Group LLC lifted its stake in Thermo Fisher Scientific by 1.6% during the first quarter. ARS Wealth Advisors Group LLC now owns 1,563 shares of the medical research company’s stock valued at $778,000 after purchasing an additional 25 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 400 shares of the company’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,066 shares of company stock worth $14,182,963. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 1.7%

TMO stock opened at $480.84 on Friday. The firm has a market cap of $181.57 billion, a PE ratio of 27.81, a PEG ratio of 2.52 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $623.77. The company has a fifty day simple moving average of $471.11 and a 200 day simple moving average of $450.27. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.95%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, September 7th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. Raymond James Financial restated an “outperform” rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research report on Thursday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $592.24.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.